The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated significant gains, the end of its patent opened the avenue to off-brand alternatives, https://emilypkbw477447.canariblogs.com/the-copyright-and-the-pharmaceutical-industry-a-volatile-bet-56758434